Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 1,108 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $25.00, for a total value of $27,700.00. Following the completion of the sale, the chief financial officer directly owned 187,209 shares of the company’s stock, valued at approximately $4,680,225. This represents a 0.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Omada Health Price Performance
OMDA stock traded up $0.86 during mid-day trading on Monday, reaching $24.55. 1,404,748 shares of the company’s stock were exchanged, compared to its average volume of 1,250,157. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The stock’s 50 day moving average is $22.27 and its 200 day moving average is $17.20. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 491.00 and a beta of 1.73.
Omada Health (NASDAQ:OMDA – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. On average, research analysts forecast that Omada Health, Inc. will post 0.09 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omada Health
Analysts Set New Price Targets
A number of brokerages recently issued reports on OMDA. Canaccord Genuity Group upped their target price on Omada Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citizens Jmp increased their price objective on Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. BMO Capital Markets restated an “outperform” rating and set a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Wall Street Zen raised shares of Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Omada Health presently has an average rating of “Moderate Buy” and an average price target of $26.50.
View Our Latest Stock Analysis on Omada Health
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
- Five stocks we like better than Omada Health
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
